Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:237
Structure:
Synonyms:
1,4-Pentanediamine, N4-(6-chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-
130-42-7
130-42-7 (mono-hydrochloride)
2-Methoxy-6-chloro-9-diethylaminopentylaminoacridine
3-Chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine
316-05-2
316-05-2 (dimesylate)
4-N-(6-chloro-2-methoxyacridin-9-yl)-1-N,1-N-diethylpentane-1,4-diamine
6-Chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxyacridine
6151-30-0
6151-30-0 (di-hydrochloride, di-hydrate)
6151-30-0 (DIHYDROCHLORIDE DIHYDRATE)
66777-81-9
69-05-6
69-05-6 (di-hydrochloride)
69-05-6 (DIHYDROCHLORIDE)
78901-94-7
78901-94-7 (monoacetate)
83-89-6
AB00053540
AC1L18SD
Acirchine
Acrichine
Acridine, 6-chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxy-
Acridine, 6-chloro-9-[[4-(diethylamino)-1-methylbutyl]amino]-2-methoxy-
Acrinamine
Acriquine
AI3-04467
AIDS-002327
AIDS002327
AKOS000541535
Akrichin
Antimalarina
Atabrine
atebrin
Atebrine
BAS 00439963
BPBio1_000348
BRD-A45889380-336-03-4
BSPBio_000316
BSPBio_002112
C07339
CCG-205050
CCRIS 8633
CHEBI:8711
CHEMBL7568
Chinacrin
cMAP_000067
D08179
DB01103
Dial
DivK1c_000101
EINECS 201-508-7
Erion
Erion Hydrochloride
GNF-PF-5448
Haffkinine
HMS2090L03
HSDB 3253
IDI1_000101
Italchin
Italchine
KBio1_000101
KBio2_001409
KBio2_002507
KBio2_003977
KBio2_005075
KBio2_006545
KBio2_007643
KBio3_001612
KBio3_002985
KBioGR_001011
KBioGR_002507
KBioSS_001409
KBioSS_002515
Lopac0_000970
LS-14293
Malaricida
Mecryl
Mepacrina
Mepacrina [INN-Spanish]
Mepacrine
Mepacrine (INN)
Mepacrine [INN:BAN]
Mepacrinum
Mepacrinum [INN-Latin]
Methoquine
Metochin
MS-1557
N'-(6-Chloro-2-methoxy-acridin-9-yl)-N,N-diethyl-pentane-1,4-diamine
N'-(6-Chloro-2-methoxy-acridin-9-yl)-N,N-diethyl-pentane-1,4-diamine dihydrochloride
N'-(6-chloro-2-methoxyacridin-9-yl)-N,N-diethylpentane-1,4-diamine
N(4)-(6-chloro-2-methoxy-9-acridinyl)-N(1),N(1)-diethyl-1,4-pentanediamine
N*4*-(6-Chloro-2-methoxy-acridin-9-yl)-N*1*,N*1*-diethyl-pentane-1,4-diamine
N4-(6-Chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-1,4-pentanediamine
NCGC00015874-02
NCGC00015874-03
NCGC00015874-04
NCGC00162300-01
nchembio.215-comp6
nchembio873-comp30
NCI60_000926
NINDS_000101
N~4~-[6-chloro-2-(methyloxy)acridin-9-yl]-N~1~,N~1~-diethylpentane-1,4-diamine
Palacrin
Palusan
Pentilen
Prestwick0_000318
Prestwick1_000318
Prestwick2_000318
Prestwick3_000318
Quinacrin
Quinacrine
Quinacrine Dihydrochloride
Quinactine
RP-866 (Dihydrochloride dihydrate)
SN-390 (Dihydrochloride dihydrate)
SPBio_000676
SPBio_002535
Spectrum2_000888
Spectrum3_000606
Spectrum4_000496
Spectrum5_001405
Spectrum_000929
St 439
STL061087
ATC-Codes:

Target

show target details
Uniprot ID:HEXB_RAT
Synonyms:
Beta-hexosaminidase subunit beta
Beta-N-acetylhexosaminidase subunit beta
Hexosaminidase subunit B
N-acetyl-beta-glucosaminidase subunit beta
EC-Numbers:3.2.1.52
Organism:Rat
Rattus norvegicus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

3218612
Quinacrine prevention of intestinal ischaemic mucosal damage is partly mediated through inhibition of intraluminal phospholipase A2.. T Otamiri (1988) Agents and actions display abstract
The influence of total ischaemia and revascularization on luminal phospholipid metabolism in the rat small intestine was investigated. Two hours of total ischaemia followed by five minutes of revascularization caused increases in phospholipase A2 activity, and lysophosphalidylcholine content in the gut lumen. The above treatment also resulted in mucosal damage expressed as an increase in N-acetyl-beta-glucosaminidase activity in the lumen. Pretreatment of animals with the phospholipase A2 inhibitor, quinacrine prevented the increases in luminal phospholipase A2 activity and mucosal damage following ischaemia and revascularization. Intraluminal injection of either phospholipase A2 purified from snake venom or Triton X-100 resulted in increased activity of N-acetyl-beta-glucosaminidase in the luminal content. Again, quinacrine pretreatment of animals prevented the increases in mucosal permeability and activity of N-acetyl-beta-glucosaminidase after intraluminal injection of purified phospholipase A2. On the other hand quinacrine pretreatment had no influence on the observed effects of Triton X-100 treatment. These findings suggest that an increase in luminal phospholipase A2 could be involved in mediating the mucosal injury caused by small intestinal ischaemia.